UTokyo IPC Co., Ltd.
![UTokyo IPC Co., Ltd.](https://tokyosuteam.metro.tokyo.lg.jp/en/cms/wp-content/uploads/1970/10/035-37.jpg)
- PoC
- Overseas Development
- Seed
- University-related
- Deep Tech
Overview
Established in 2016, UTokyo Innovation Platform Co., Ltd. (UTokyoIPC) stands as the first venture capital firm wholly owned by the University of Tokyo. Their primary activities encompass three key areas: ① Investing through the IPC1 Fund and the AOI No.1 Fund, which together account for an investment capacity of 50 billion yen. ② Through their 1stRound incubator program, UTokyoIPC collaborates with 13 Japanese universities and harnesses significant contributions from 24 leading corporations to swiftly bolster and nurture the growth of early-stage academic startups. ③ The DEEPTECH DIVE platform steers professionals, such as researchers, engineers, and veteran business individuals, towards prospects in the deep tech realm. With these strategic endeavors, UTokyoIPC is committed to magnifying innovation not just within the confines of the University of Tokyo but also throughout other prominent Japanese universities.
Initiative details
In our initiative, we tackle domestic deep tech startups’ challenges like foreign market entry barriers and cultural mismatches. Our solution? A system designed for their global success.
We’re partnering with top universities and research hubs to tap into elite talent, aiming to shift academic prowess into startup success. Our unique ‘Team Fusion’ process combines tech and business minds for balanced startup teams. Alongside, our ‘Global Navigator’ program, developed with academic partners, arms startups with essential skills for international markets.
Recognizing the pharmaceutical sector’s potential, we’re introducing ‘PharmaFrontiers’ to support drug discovery startups, ensuring they’re primed for global leadership.
Progress
KPIs & Achievements
Can be viewed by scrolling horizontally.
Outcomes / As of June 31, 2024
*1 : Promising academically-focused pharmaceutical startups compatible with global standards that are expanding overseas
Outputs / As of June 31, 2024
*2 : Screening by major companies and external VCs for applicants related to startups of universities and research institutions
*3 : Screening specialized in pharmaceutical seed-staged startups related to universities and research institutions
SU Support Info
・Applications not available at this time